These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 35471559)

  • 1. Global Regulatory and Public Health Initiatives to Advance Pediatric Drug Development for Rare Diseases.
    Epps C; Bax R; Croker A; Green D; Gropman A; Klein AV; Landry H; Pariser A; Rosenman M; Sakiyama M; Sato J; Sen K; Stone M; Takeuchi F; Davis JM
    Ther Innov Regul Sci; 2022 Nov; 56(6):964-975. PubMed ID: 35471559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Achieving big with small: quantitative clinical pharmacology tools for drug development in pediatric rare diseases.
    Ahmed MA; Burnham J; Dwivedi G; AbuAsal B
    J Pharmacokinet Pharmacodyn; 2023 Dec; 50(6):429-444. PubMed ID: 37140724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulatory strategies for rare diseases under current global regulatory statutes: a discussion with stakeholders.
    Mulberg AE; Bucci-Rechtweg C; Giuliano J; Jacoby D; Johnson FK; Liu Q; Marsden D; McGoohan S; Nelson R; Patel N; Romero K; Sinha V; Sitaraman S; Spaltro J; Kessler V
    Orphanet J Rare Dis; 2019 Feb; 14(1):36. PubMed ID: 30736861
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The 2023 Latin America report of the
    Hartinger SM; Palmeiro-Silva YK; Llerena-Cayo C; Blanco-Villafuerte L; Escobar LE; Diaz A; Sarmiento JH; Lescano AG; Melo O; Rojas-Rueda D; Takahashi B; Callaghan M; Chesini F; Dasgupta S; Posse CG; Gouveia N; Martins de Carvalho A; Miranda-Chacón Z; Mohajeri N; Pantoja C; Robinson EJZ; Salas MF; Santiago R; Sauma E; Santos-Vega M; Scamman D; Sergeeva M; Souza de Camargo T; Sorensen C; Umaña JD; Yglesias-González M; Walawender M; Buss D; Romanello M
    Lancet Reg Health Am; 2024 May; 33():100746. PubMed ID: 38800647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Impact of Inflammatory Bowel Disease in Canada 2018: Children and Adolescents with IBD.
    Carroll MW; Kuenzig ME; Mack DR; Otley AR; Griffiths AM; Kaplan GG; Bernstein CN; Bitton A; Murthy SK; Nguyen GC; Lee K; Cooke-Lauder J; Benchimol EI
    J Can Assoc Gastroenterol; 2019 Feb; 2(Suppl 1):S49-S67. PubMed ID: 31294385
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Orphan Medicines for Pediatric Use: A Focus on the European Union.
    Bolislis WR; Corriol-Rohou S; Hill-Venning C; Hoogland H; Joos A; King D; Kitcatt V; Le Visage G; Kühler TC
    Clin Ther; 2019 Dec; 41(12):2630-2642. PubMed ID: 31704041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of Incentive Policies and Initiatives on Orphan Drug Development in China: Challenges, Reforms and Implications.
    Zhao Z; Pei Z; Hu A; Zhang Y; Chen J
    Orphanet J Rare Dis; 2023 Jul; 18(1):220. PubMed ID: 37501126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rare disease clinical trials in the European Union: navigating regulatory and clinical challenges.
    Mishra S; Venkatesh MP
    Orphanet J Rare Dis; 2024 Jul; 19(1):285. PubMed ID: 39085891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Model-Informed Approach Supporting Drug Development and Regulatory Evaluation for Rare Diseases.
    Li RJ; Ma L; Li F; Li L; Bi Y; Yuan Y; Li Y; Xu Y; Zhang X; Liu J; Bhattaram VA; Wang J; Schuck R; Pacanowski M; Zhu H
    J Clin Pharmacol; 2022 Dec; 62 Suppl 2():S27-S37. PubMed ID: 36461744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Digital Approaches to Remote Pediatric Health Care Delivery During the COVID-19 Pandemic: Existing Evidence and a Call for Further Research.
    Badawy SM; Radovic A
    JMIR Pediatr Parent; 2020 Jun; 3(1):e20049. PubMed ID: 32540841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Navigating the Regulatory Landscape to Develop Pediatric Oncology Drugs: Expert Opinion Recommendations.
    Barry E; Walsh JA; Weinrich SL; Beaupre D; Blasi E; Arenson DR; Jacobs IA
    Paediatr Drugs; 2021 Jul; 23(4):381-394. PubMed ID: 34173206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Innovations in Clinical Development in Rare Diseases of Children and Adults: Small Populations and/or Small Patients.
    Beckman RA; Antonijevic Z; Ghadessi M; Xu H; Chen C; Liu Y; Tang R
    Paediatr Drugs; 2022 Nov; 24(6):657-669. PubMed ID: 36241954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Regulatory Incentive Programs on the Future of Pediatric Drug Development.
    Yen E; Davis JM; Milne CP
    Ther Innov Regul Sci; 2019 Sep; 53(5):609-614. PubMed ID: 30983385
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can Innovative Trial Designs in Orphan Diseases Drive Advancement of Treatments for Common Neurological Diseases?
    Stephenson D; Ollivier C; Brinton R; Barrett J
    Clin Pharmacol Ther; 2022 Apr; 111(4):799-806. PubMed ID: 35034352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medicinal Product Development and Regulatory Agilities Implemented During the Early Phases of the COVID-19 Pandemic: Experiences and Implications for the Future-An Industry View.
    Geraci G; Bernat J; Rodier C; Acha V; Acquah J; Beakes-Read G
    Ther Innov Regul Sci; 2023 Sep; 57(5):940-951. PubMed ID: 37266868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose-finding studies in drug development for rare genetic diseases.
    Wang L; Wang J; Feng J; Doi M; Pepe S; Pacanowski M; Schuck RN
    Orphanet J Rare Dis; 2022 Apr; 17(1):156. PubMed ID: 35382851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of the COVID-19 pandemic on US Food and Drug Administration-funded clinical trials and natural history studies for rare diseases.
    Miller KL; Miller Needleman KI
    Contemp Clin Trials; 2023 Jun; 129():107198. PubMed ID: 37068589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Challenges of drug development during the COVID-19 pandemic: Key considerations for clinical trial designs.
    Shi J; Xiao Y; Zhang Y; Geng D; Cong D; Shi KX; Knapp RJ
    Br J Clin Pharmacol; 2021 May; 87(5):2170-2185. PubMed ID: 33119136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.